English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.48 |
| Open | 1.45 |
| 1-Year Change | -32.87% |
| Day's Range | 1.4 - 1.49 |
Rockwell Medical, Inc. is a commercial-stage, biopharmaceutical company. The Company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.
BRIEF: For the nine months ended 30 September 2021, Rockwell Medical Inc revenues decreased 1% to $46.6M. Net loss increased 7% to $23.7M. Revenues reflect United States segment decrease of 1% to $41.9M. Higher net loss reflects Research and Product Development increase of 5% to $5.4M (expense), Interest Income decrease of 92% to $18K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.32 to -$0.25.
Common Stock no Par, 04/11, N/A auth., 17,843,608 issd. Insiders control 14.55%. IPO:1/98,1.8M Common @ $4 + 2.7M Warrants @ $.10 by Mason Hill & Co., Inc. *NOTE: FY'96 = 2 months due to 10/25/96 inception. All financials prior to 2/19/97 are Predecessor.
